Form 4: REGENXBIO CEO Curran Simpson Reports Stock Transactions

CEO Curran Simpson of REGENXBIO Inc. reports acquisition and disposal of company stock and stock options.

Summary

• On January 2, 2025, Curran Simpson, CEO of REGENXBIO Inc., reported transactions involving the company's stock.
• Simpson disposed of 11,917 shares of common stock at $7.73 to cover taxes related to vesting restricted stock units.
• He also acquired 98,912 shares of common stock through a restricted stock unit award.
• Following these transactions, Simpson directly owns 257,032 shares of REGENXBIO common stock.
• Simpson was also granted options to buy 476,606 shares of common stock at an exercise price of $7.86, exercisable starting January 2, 2026.
• After the reported transactions, Simpson directly owns 476,606 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are routine and related to executive compensation. The disposal of shares for tax purposes is a common practice and doesn't necessarily indicate a negative outlook.

Positives

• The grant of restricted stock units and stock options to the CEO aligns his interests with those of the shareholders.
• The vesting schedules for the RSUs and stock options incentivize long-term performance and retention.

Negatives

• The disposal of 11,917 shares, even for tax purposes, could be perceived negatively by some investors, although it's a common practice.

Future Outlook

The restricted stock units vest over four years, starting January 1, 2026, and the stock options vest over four years starting January 2, 2026, contingent upon continuous service to the Issuer.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's confidence in the company's future prospects.

Comparison to Industry Standards

• Stock option and RSU grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent.
• Vesting schedules are typically structured to align executive incentives with long-term shareholder value creation, similar to practices at companies like BioMarin and Sarepta Therapeutics.
• The size of the grant and the vesting schedule would be benchmarked against peer companies of similar market capitalization and stage of development.

Stakeholder Impact

• The transactions have a minor impact on shareholders, as they reflect standard executive compensation practices.
• Employees may view the grants positively, as they signal the company's commitment to incentivizing and retaining key personnel.

Key Dates